Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

NCT07136779 is registered in ClinicalTrials.gov with VelaVigo Bio Inc as lead sponsor.

NCT NCT07136779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES
Lead sponsor
VelaVigo Bio Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 23, 2025
Completion date
July 1, 2028
Enrollment
310 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

participants with advanced solid tumor malignancies